- Home
- CABA vs FBRX Comparison
CABA vs FBRX Comparison
Compare CABA & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- FBRX
- Stock Information
- Founded
- CABA 2017
- FBRX N/A
- Country
- CABA United States
- FBRX United States
- Employees
- CABA 167
- FBRX N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- CABA Health Care
- FBRX Health Care
- Exchange
- CABA Nasdaq
- FBRX Nasdaq
- Market Cap
- CABA 174.7M
- FBRX 154.5M
- IPO Year
- CABA 2019
- FBRX N/A
- Fundamental
- Price
- CABA $2.04
- FBRX $12.10
- Analyst Decision
- CABA Strong Buy
- FBRX Strong Buy
- Analyst Count
- CABA 8
- FBRX 3
- Target Price
- CABA $12.75
- FBRX $68.00
- AVG Volume (30 Days)
- CABA 1.3M
- FBRX 75.9K
- Earning Date
- CABA 11-13-2025
- FBRX 11-13-2025
- Dividend Yield
- CABA N/A
- FBRX N/A
- EPS Growth
- CABA N/A
- FBRX N/A
- EPS
- CABA N/A
- FBRX N/A
- Revenue
- CABA N/A
- FBRX N/A
- Revenue This Year
- CABA N/A
- FBRX N/A
- Revenue Next Year
- CABA N/A
- FBRX N/A
- P/E Ratio
- CABA N/A
- FBRX N/A
- Revenue Growth
- CABA N/A
- FBRX N/A
- 52 Week Low
- CABA $0.99
- FBRX $4.11
- 52 Week High
- CABA $5.46
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- CABA 71.47
- FBRX 62.12
- Support Level
- CABA $1.63
- FBRX $10.11
- Resistance Level
- CABA $1.74
- FBRX $11.57
- Average True Range (ATR)
- CABA 0.12
- FBRX 0.83
- MACD
- CABA 0.05
- FBRX 0.10
- Stochastic Oscillator
- CABA 89.44
- FBRX 86.89
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).